Summarized by Masters of Longevity from Longevity Docs News.
New obesity therapeutics from a diabetes meeting are previewed, highlighting emerging drug classes and what readers should expect from the coverage.
Key Takeaways
- Novo's semaglutide plus cagrilintide produced 22.4% mean weight loss at one year in trial data.
- Lilly's eloralintide plus tirzepatide reached 23% weight loss compared with 14.8% for tirzepatide alone.
- Lilly's oral orforglipron showed no excess cardiovascular risk versus insulin glargine in a 2,700+ patient trial.
